Intra-Cellular optimistic on lumateperone's future in bipolar despite mixed Phase III results

While one of its trials missed the primary endpoint, Intra-Cellular is hopeful that the robust treatment response seen in the other Phase III lumateperone trial along with a lack of tolerable treatment options for bipolar depression could be sufficient to file for approval.

On Monday, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) fell $1.76 (13%) to $11.70 for a loss of about $97 million in market cap after lumateperone met the primary endpoint in one Phase III trial to treat bipolar depression but missed it in another...